NCT05165160Completed
Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis
Local Undertaking of Resected Non-small Cell Lung Cancer by Generating a Residual Disease Outline Based on Circulating Cell-free DNA
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
Prognosis of resectable early stages NSCLC might be improved by a better knowledge of post-operative minimal residual disease (MRD). This could be achieved by studying patient with stage I to IIIA completely resected-NSCLC, comparing qualitative and quantitative features of pre- and post-operative circulating cell-free DNA (cirDNA), using MiTest. We assume that the evolution of the parameters of MiTest and relapse rate after surgery are related and expect to prove that normalization of MiTest at one month after surgery is a prognostic factor of reduced relapse at one year.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 133 (actual)
- First submitted
- 17 Dec 2021
- Start date
- 15 Feb 2022
- Primary completion date
- 2 Apr 2025
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Lung cancer
- NCT number
- NCT05165160
What you commit to
- Study type: Interventional
- Participants enrolled: 133
- From 15 Feb 2022 to the primary completion date, 2 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any previous systemic neoadjuvant treatment: targeted therapy, chemotherapy, immune checkpoint blockade
- Previous radiotherapeutic neoadjuvant treatment
- Resection margins R1 and R2
Other illness
- Multiple primary lung cancer.
- Previous malignancy during the past 3 years (except non-melanomatous skin cancer)
- Preexisting interstitial lung disease
- known HIV, active viral B hepatitis or C hepatitis
- Patient with any other situation responsible for cirDNA rate increasing (active auto-immune disease, 10 days following blood transfusion)
Age
- Woman of childbearing age without efficient contraception, breastfeeding
Other
- Non-invasive lung carcinoma
- Patient unable to attend all scheduled visits
- Patient with a legal protection measure (guardianship, curatorship)
- Vulnerable patient protected by law
Who the study is looking for
- Age: 18 years or older
- Patients with a resectable NSCLC
- Definite stage I to IIIA
- Performance status of 0, 1 or 2
- Normal end organ functions
- Written and signed informed consent form
- Subjects must be covered by public health insurance.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.